Business Wire

SPIE and the University of Birmingham Establish $800,000 Photonics-focused Education Fund

Share

SPIE, the international society for optics and photonics, and the University of Birmingham have announced the establishment of the SPIE Optics and Photonics Champion Academy fund. The new endowment was announced this morning, during SPIE Photonex + Vacuum Technologies in Glasgow, Scotland.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210930005066/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

University of Birmingham students pictured in the UK Quantum Technology Hub, home to the SPIE Optics and Photonics Champions Academy. (Photo: Business Wire)

The $400,000 gift from the SPIE Endowment Matching Program will be matched 100% by the university, and the $800,000 fund will create and support the SPIE Optics and Photonics Champion Academy. The cohort-focused program will engage in areas of public interest in the fields of quantum technology and biomedical imaging and data sciences: one of the first projects will address pandemics. The program will be led by Professor and Principal Investigator of the UK Quantum Technology Hub Sensors and Timing Kai Bongs, and Professor of Computational Life Sciences Iain Styles.

The SPIE Optics and Photonics Champion Academy will support University of Birmingham students in a variety of ways which include expanding cross-disciplinary educational opportunities in optics and photonics; offering students hands-on support and training to become influential science communicators and advocates of optics and photonics; and by utilizing a range of stipends, awards, and activity grants, which will be supplemented with professional development and mentoring opportunities from the university’s academic leaders as well as from external experts.

The program will focus particularly on students in underrepresented groups, early-career researchers, and PhD students in order to establish and build a broad, diverse, and inclusive network of science advocates, especially in the area of optics and photonics.

“We are delighted to be able to work with SPIE to launch this unique Academy at the University of Birmingham,” said Professor Bongs. “This initiative will help to accelerate the growth of optics and photonics expertise, which will have great impact far beyond the university. Our hope is to not only encourage this learning, but to also create awareness of the huge importance of this subject area in tackling real-world problems.”

“By equipping early-career optics and photonics researchers and PhD students with skills in advanced data analysis, we will help to accelerate the translation of these exciting technologies from the laboratory to their adoption in real-world applications,” added Professor Styles. “Our SPIE Champions will be able to work with experts in diverse application areas such as healthcare and climate monitoring to develop end-to-end optics-based solutions with integrated analytics for some of our most pressing challenges.”

“By offering direct, experiential training in quantum technology and biomedical imaging as well as highlighting various career options in the field, the SPIE Optics and Photonics Champion Academy will develop a natural pipeline of future professional scientists and engineers in these fields,” noted SPIE President David Andrews. “And by encouraging students to actively raise awareness of the impact of optics and photonics to their contemporaries, peers, and younger colleagues, the program will be creating visible, engaged role models for future generations.”

The SPIE Endowment Matching Program was established in 2019 to increase international capacity in the teaching and research of optics and photonics, and to date has given more than $3.4 million in matching gifts, resulting in more than $9 million in dedicated funds. The SPIE Endowment Matching Program supports optics and photonics education and the future of the industry by contributing a match of up to $500,000 per award to college and university programs with optics and photonics degrees, or with other disciplines allied to the SPIE mission.

About SPIE

SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Daneet Steffens
Public Relations Manager
daneets@spie.org
+1 360 685 5478
@SPIEtweets

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye